Kiniksa Pharmaceuticals (NASDAQ: KNSA) is set to give its latest quarterly earnings report on Tuesday, 2026-02-24. Here's ...
Investors in Kiniksa Pharmaceuticals International, plc KNSA need to pay close attention to the stock based on moves in the ...
Zacks Investment Research on MSN
Kiniksa Pharmaceuticals International, plc (KNSA) earnings expected to grow: Should you buy?
Wall Street expects a year-over-year increase in earnings on higher revenues when Kiniksa Pharmaceuticals International, plc ...
Sanj Patel, CEO, stated that "ARCALYST revenue continues to grow, driven by the expanding adoption of IL-1 alpha and beta inhibition across the recurrent pericarditis population." He highlighted a 65% ...
Fintel on MSN
Canaccord Genuity initiates coverage of Kiniksa Pharmaceuticals International (KNSA) with buy recommendation
Fintel reports that on February 19, 2026, Canaccord Genuity initiated coverage of Kiniksa Pharmaceuticals International (NasdaqGS:KNSA) with a Buy recommendation. Analyst Price Forecast Suggests 23.60 ...
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is one of the most promising mid-cap healthcare stocks under $50. On December 12, Wells Fargo analyst Eva Fortea Verdejo indicated her bullish ...
Phase III study will be "sufficient and pivotal for registration in the U.S." Kiniksa Pharmaceuticals ( KNSA +1.56%) ...
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of -40.71% and +0.66%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what ...
Strs Ohio purchased a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & ...
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2025 Earnings Call Transcript February 24, 2026 Kiniksa Pharmaceuticals, Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results